Arn CR et al. Tisotumab vedotin safety and tolerability in clinical practice: Managing adverse events. J Adv Pract Oncol 2023;14(2):139-52. Abstract

Coleman RL et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): A multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 2021;22(5):609-19. Abstract

Eskander RN et al.  Pembrolizumab plus chemotherapy in advanced endometrial cancer. N Engl J Med 2023;[Online ahead of print]. Abstract

Eskander RN et al. Pembrolizumab versus placebo in addition to carboplatin and paclitaxel for measurable stage 3 or 4a, stage 4b or recurrent endometrial cancer: The phase 3, NRG GY018 study. SGO 2023;Abstract 264.

Makker V et al. Randomized phase III study of maintenance selinexor versus placebo in endometrial cancer (ENGOT-EN5/GOG-3055/SIENDO): Impact of subgroup analysis and molecular classification. ASCO 2022;Abstract 5511.

Mirza MR et al. Dostarlimab for primary advanced or recurrent endometrial cancer. N Engl J Med 2023;[Online ahead of print]. Abstract

Mirza MR et al. Dostarlimab in combination with chemotherapy for the treatment of primary advanced or recurrent endometrial cancer: A placebo-controlled randomized phase 3 trial (ENGOT-EN6-NSGO/GOG-3031/RUBY). SGO 2023;Abstract 265.

Vergote I et al. Prospective double blind, randomized phase III ENGOT EN5/GOG 3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first line chemotherapy for advanced or recurrent endometrial cancer. SGO 2022;Abstract 249.